Medical treatment update on pulmonary arterial hypertension

Cher Y. Enderby, Charles Dwayne Burger

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.

Original languageEnglish (US)
Pages (from-to)264-272
Number of pages9
JournalTherapeutic Advances in Chronic Disease
Volume6
Issue number5
DOIs
StatePublished - Sep 27 2015

Fingerprint

Pulmonary Hypertension
Prostaglandins
Phosphodiesterase 5 Inhibitors
Endothelin-1
Epoprostenol
United States Food and Drug Administration
Nitric Oxide
Chronic Disease
Therapeutics
Lung
Endothelin Receptor Antagonists

Keywords

  • macitentan
  • oral treprostinil
  • pulmonary arterial hypertension
  • riociguat

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Medical treatment update on pulmonary arterial hypertension. / Enderby, Cher Y.; Burger, Charles Dwayne.

In: Therapeutic Advances in Chronic Disease, Vol. 6, No. 5, 27.09.2015, p. 264-272.

Research output: Contribution to journalArticle

@article{cec9b80c28f2451a8df75cd398f2bf51,
title = "Medical treatment update on pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.",
keywords = "macitentan, oral treprostinil, pulmonary arterial hypertension, riociguat",
author = "Enderby, {Cher Y.} and Burger, {Charles Dwayne}",
year = "2015",
month = "9",
day = "27",
doi = "10.1177/2040622315590757",
language = "English (US)",
volume = "6",
pages = "264--272",
journal = "Therapeutic Advances in Chronic Disease",
issn = "2040-6223",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Medical treatment update on pulmonary arterial hypertension

AU - Enderby, Cher Y.

AU - Burger, Charles Dwayne

PY - 2015/9/27

Y1 - 2015/9/27

N2 - Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.

AB - Pulmonary arterial hypertension is a chronic, progressive disease of the pulmonary vasculature resulting in poor outcomes if left untreated. The management of group 1 pulmonary arterial hypertension has included the use of prostanoids, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists targeting the prostacyclin, endothelin-1, and nitric oxide pathways. Three new medications have been approved by the US Food and Drug Administration over the past couple of years. Macitentan is the newest endothelin receptor antagonist, riociguat is a soluble guanylate cyclase stimulator, and treprostinil diolamine is the first oral prostanoid. This review will focus on the key trials leading to their approval, special considerations for each medication, and their potential place in therapy. The use of combination therapy as initial therapy in pulmonary arterial hypertension will also be discussed.

KW - macitentan

KW - oral treprostinil

KW - pulmonary arterial hypertension

KW - riociguat

UR - http://www.scopus.com/inward/record.url?scp=84940020648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940020648&partnerID=8YFLogxK

U2 - 10.1177/2040622315590757

DO - 10.1177/2040622315590757

M3 - Article

AN - SCOPUS:84940020648

VL - 6

SP - 264

EP - 272

JO - Therapeutic Advances in Chronic Disease

JF - Therapeutic Advances in Chronic Disease

SN - 2040-6223

IS - 5

ER -